Indolent Non-Hodgkin Lymphoma
Conditions
Keywords
indolent lymphoma, novel agents, chemotherapy free treatment, ibrutinib, obinutuzumab, GA101
Brief summary
Primary Objectives The primary objective of this study is to evaluate the efficacy of the chemotherapy-free combination of ibrutinib and obinutuzumab (GA 101) in patients with previously untreated follicular lymphoma (FL) and a high tumor burden. Primary endpoint to be observed for this is the rate of progression free survival one year after start of therapy. Hypothesis The hypothesis of the study is that ibrutinib in combination with obinutuzumab will achieve response rates (CR and PR), rates of MRD negativity and PFS which are comparable to currently used standard rituximab-chemotherapy combinations such as R-CHOP or R-bendamustine in subjects with previously untreated FL and a high tumor burden.
Detailed description
OVERVIEW OF STUDY DESIGN This is a prospective, multicenter phase 2 study in up to 98 subjects with previously untreated FL and a high tumor burden in advanced stages and in need of therapy. The study will include a central monitoring of MRD by PCR, a central pathologic review and complimentary research projects including monitoring of immune response. The study therapy comprises an initial 6 cycles of ibrutinib plus obinutuzumab followed by an additional 24 months of ibrutinib plus obinutuzumab maintenance. In patients being MRD negative at 30 months, i.e. at the end of ibrutinib plus obinutuzumab maintenance, and without clinical progression no further treatment is given while MRD monitoring is continued. MRD monitoring will be regularly performed on peripheral blood samples collected before the start of therapy and at months 3, 6, 9, 12, 18, 24 and 30 respectively. Subsequently, MRD analyses will be performed every 6 months until clinical progression of the disease or for a maximum of 4 years (until the end of the study). If MRD assessment on peripheral blood samples turns from positive to negative within the first 30 months, confirmatory blood and bone marrow samples should be taken 6 months thereafter. In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months. An independent Data Monitoring Committee (DMC) will be formed and constituted. The independent DMC will review the safety of the treatment and make recommendations as to the further conduct of the study. The data generated by this phase II study should serve as the basis for a subsequent randomized phase III study comparing the chemotherapy-free combination of ibrutinib plus obinutuzumab with standard immune-chemotherapy.
Interventions
DRUGIbrutinib
Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
DRUGGA 101
Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
Sponsors
Hoffmann-La Roche
Janssen-Cilag G.m.b.H
Ludwig-Maximilians - University of Munich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Histologically confirmed follicular lymphoma grade 1, 2 or 3A with a lymph node biopsy performed within 12 months before study entry and with material available for central review and complementary scientific analyses * Ann Arbor stage III/IV, or stage II not suitable for radiotherapy, or stage II bulky disease * Age ≥ 18 years * No prior lymphoma therapy * Need for start of therapy as defined by: * bulky disease at study entry according to the GELF criteria (nodal or extranodal mass \>7 cm in its greater diameter) * and/or B symptoms (fever, drenching night sweats, or unintentional weight loss of \>10% of normal body weight over a period of 6 months or less) * and/or hematopoietic insufficiency (granulocytopenia \< 1.500/µl, Hb \< 10 g/dl, thrombocytopenia \< 100.000/µl) * compressive syndrome or high risk for compression syndrome * and/or pleural/peritoneal effusion * and/or symptomatic extranodal manifestations * At least one bi-dimensionally measurable lesion (\> 2 cm in its largest dimension by CT scan or MRI) * Performance status ≤ 2 on the ECOG scale * Adequate hematologic function (unless abnormalities are related to NHL), defined as follows: * Hemoglobin ≥ 9.0 g/dL * Absolute neutrophil count ≥ 1500 /µl * Platelet count ≥ 75000 /µl * Women are not breast feeding, are using highly effective contraception, are not pregnant, and agree not to become pregnant during participation in the trial and during the 18 months thereafter (pregnancy testing is mandatory for premenopausal women). * Men agree not to father a child during participation in the trial and during the 18 months thereafter. * Written informed consent
Exclusion criteria
* \- Transformation to high-grade lymphoma (secondary to low grade FL) * Grade 3B follicular lymphoma * Presence or history of CNS disease (either CNS lymphoma or leptomeningeal lymphoma). * Known hypersensitivity to any of the study drugs * Known sensitivity to murine products * Regular use of corticosteroids during the last 4 weeks, unless administered at a dose equivalent to \< 20 mg/day prednisone. * Concomitant use of strong CYP3A4 inhibitors and / or oral anticoagulants (warfarin and/or phenprocoumon) * Prior or concomitant malignancies except: * non-melanoma skin cancer or adequately treated in carcinoma in situ of the cervix * Other malignant diseases not specified above which have been curatively treated by surgery alone and from which subject is disease-free for ≥5 years without further treatment * Serious disease interfering with a regular therapy according to the study protocol: * Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification * pulmonary (e.g. chronic lung disease with hypoxemia) * endocrine (e.g. severe, not sufficiently controlled diabetes mellitus) * renal insufficiency (unless caused by the lymphoma): creatinine \> 2x normal value and/or creatinine clearance \< 50 ml/min) * impairment of liver function (unless caused by the lymphoma): transaminases \> 3x normal or bilirubin \> 2,0 mg/dl (unless caused by known Morbus Meulengracht \[Gilbert-Meulengracht-Syndrome\]) * Positive test results for chronic HBV infection (defined as positive HBsAg serology) Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination or prior but cured hepatitis B are eligible. * Positive test results for hepatitis C (hepatitis C virus \[HCV\] antibody serology testing). Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA. * Known history of HIV seropositive status. * Patients with a history of confirmed PML * Vaccination with a live vaccine within 28 days prior to registration * Recent major surgery (within 4 weeks prior to the start of Cycle 1) * History of stroke or intracranial hemorrhage within 6 months prior to registration * Serious underlying medical conditions, which could impair the ability of the patient to undergo the treatment offered in the study (e.g. ongoing infection, gastric ulcers, active autoimmune disease) * Treatment within a clinical trial within 30 days prior to trial entry. * Prior organ, bone marrow or peripheral blood stem cell transplantation * Known or persistent abuse of medication, drugs or alcohol * Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | one year progress free survival | The rate of patients archiving a progression free survival of more than one year after registration (one-year PFS) will serve as early readout for efficacy and will be the primary endpoint of this trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CR | one year after start of therapy and at 30 months after end of maintenance | CR rates at end of induction CR rates one year after start of therapy CR rates after end of maintenance therapy (at 30 months after start of therapy: CR30) |
| PR | one year after start of therapy and at 30 months after end of maintenance | PR rates at end of induction PR rates one year after start of therapy PR rates after end of maintenance therapy (at 30 months after start of therapy: CR30) |
| SD | one year after start of therapy and at 30 months after end of maintenance | SD rates at end of induction |
| Duration of response | 4,5 up to 6,5 years through study completion | Duration of Response |
| Percentage of Progression | 4,5 up to 6,5 years through study completion | Percentage of progression during induction and maintenance therapy |
| TTF after start of therapy | 4,5 up to 6,5 years through study completion | Time to treatment failure after start of therapy (failure defined by failure to achieve a CR/PR after 6 months or progression after CR or PR or death in remission) |
| three-year-PFS | three years after start of therapy | Progression free survival after start of therapy (continuous observation) * three-year-PFS |
| Treatment associated adverse events | 4,5 up to 6,5 years through study completion | Treatment associated adverse events |
| Percentage of MRD negative patients during therapy | 4,5 up to 6,5 years through study completion | Percentage of MRD negative patients during induction therapy (midterm), after induction therapy and after maintenance therapy |
| Duration of molecular remission | 4,5 up to 6,5 years through study completion | Duration of molecular remission for MRD negative patients after the end of induction and maintenance |
| Percentage of secondary transformation | 4,5 up to 6,5 years through study completion | Percentage of secondary Transformation to aggressive lymphoma |
| Percentage of secondary malignancies | 4,5 up to 6,5 years through study completion | Percentage of secondary malignancies |
| Time to first secondary malignancy | 4,5 up to 6,5 years through study completion | Time to first secondary malignancy |
| Time to next anti-lymphoma therapy / time to next chemotherapy based treatment | 4,5 up to 6,5 years through study completion | Time to next anti-lymphoma therapy and time to next chemotherapy based treatment |
Countries
Germany
Outcome results
None listed